JPMorgan and Mizuho raised their price targets for Humana Inc. on June 8, 2026 [3].
These adjustments reflect a shift in analyst sentiment regarding the company's financial trajectory. As a major player in the U.S. healthcare market, Humana's valuation often serves as a bellwether for the broader managed-care sector.
JPMorgan analyst Lisa Gill increased the price target for the company to $316, up from a previous target of $214 [1]. Despite the significant increase in the projected share price, JPMorgan maintained a Neutral rating on the stock [1].
Mizuho also revised its expectations upward on June 8, 2026 [3]. The firm raised its price target to $390 from $335 [2]. Unlike JPMorgan, Mizuho kept an Outperform rating for the insurer [2].
Analysts at both firms said these changes were due to an improving managed-care outlook [1]. The revised targets suggest that the fundamental conditions affecting health insurance operations are becoming more favorable, supporting higher valuation expectations for the company.
Humana operates primarily within the United States, where it manages significant portfolios of health insurance plans. The updates from these two major financial institutions indicate a growing confidence in the company's ability to navigate current market pressures.
“JPMorgan increased the price target for the company to $316, up from a previous target of $214.”
The simultaneous upgrades from two major financial institutions suggest a broader recovery in the managed-care sector. While the differing ratings—Neutral from JPMorgan and Outperform from Mizuho—indicate some disagreement on the stock's immediate momentum, the upward movement of both price targets signals that the systemic risks previously weighing down health insurers may be stabilizing.
